Stephen Howell
Overview
Explore the profile of Stephen Howell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ford J, Pevy N, Grunewald R, Howell S, Reuber M
Epilepsia
. 2025 Feb;
PMID: 40013839
Objective: Generalist large language models (LLMs) have shown diagnostic potential in various medical contexts but have not been explored extensively in relation to epilepsy. This paper aims to test the...
2.
Fol M, Tremblay B, Pfirman S, Newton R, Howell S, Lemieux J
Commun Earth Environ
. 2025 Jan;
6(1):46.
PMID: 39866711
The Last Ice Area-located to the north of Greenland and the northern Canadian Arctic Archipelago-is expected to persist as the central Arctic Ocean becomes seasonally ice-free within a few decades....
3.
Mudumbai S, Gabriel R, Howell S, Tan J, Freundlich R, OReilly-Shah V, et al.
Anesth Analg
. 2024 Jan;
138(2):253-272.
PMID: 38215706
The role of informatics in public health has increased over the past few decades, and the coronavirus disease 2019 (COVID-19) pandemic has underscored the critical importance of aggregated, multicenter, high-quality,...
4.
Mustafa A, Corey-Bloom J, Howell S, Gilbert P, Goble D
Parkinsonism Relat Disord
. 2022 Sep;
103:115-118.
PMID: 36099752
Introduction: Huntington's disease (HD) is a progressive neurodegenerative disorder with motor, cognitive, and psychiatric symptoms that typically manifest in middle adulthood. Balance assessments may be useful for predicting disease onset...
5.
6.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Health Technol Assess
. 2021 Dec;
25(75):1-134.
PMID: 34931602
Background: Levetiracetam (Keppra, UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran, Eisai Co. Ltd, Tokyo, Japan) are licensed as monotherapy for focal epilepsy, and levetiracetam is increasingly used as a...
7.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Lancet
. 2021 Apr;
397(10282):1375-1386.
PMID: 33838758
Background: Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is...
8.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Lancet
. 2021 Apr;
397(10282):1363-1374.
PMID: 33838757
Background: Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient...
9.
McGinty R, Handel A, Moloney T, Ramesh A, Fower A, Torzillo E, et al.
J Neurol Neurosurg Psychiatry
. 2020 Nov;
92(3):291-294.
PMID: 33219046
Objective: To generate a score which clinically identifies surface-directed autoantibodies in adults with new-onset focal epilepsy, and evaluate the value of immunotherapy in this clinical setting. Methods: Prospective clinical and...
10.
Ryan S, Zhang J, Burner D, Liss M, Pittman E, Muldong M, et al.
J Transl Med
. 2020 May;
18(1):214.
PMID: 32466781
Background: Immunotherapeutic regulation of the tumor microenvironment in prostate cancer patients is not understood. Most antibody immunotherapies have not succeeded in prostate cancer. We showed previously that high-risk PCa patients...